GIMV-managed funds commit EUR 8 million to Belgian biotech company Actogenix
Funds managed by GIMV are committing EUR 8 million to the Series-A funding round of ActoGeniX, a Belgian biotech start-up and a spin-off from the VIB. GIMV and Life Sciences Partners acted as co-lead investors in the funding round, which totalled EUR 20 million. A first closing in September 2006 brought in EUR 11.5 million of capital for ActoGeniX. In this second closing a further EUR 8.5 million were gathered, including from new investors like Aescap, Ventech and Baekeland Fonds.
ActoGeniX is the fifth venture-capital backed spin-off from VIB, following Devgen, CropDesign, Ablynx and Peakadilly. The company was founded in June 2006 with seed capital from GIMV, VIB and the management team.
Further information on ActoGeniX can be found in the attached press release.
For more information, please contact:
Mr. Frank De Leenheer - Investor Relations Manager GIMV
Tel: +32 3 290 22 18 - E-mail: firstname.lastname@example.org
Mr. Patrick Van Beneden – Executive Vice President GIMV
Tel: +32 3 290 21 56 – E-mail: email@example.com